Trial Profile

A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 19 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Savolitinib (Primary)
Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
Focus Therapeutic Use

Most Recent Events

20 Jul 2023 Status changed from active, no longer recruiting to discontinued due to inadequate accrual rate.
28 Jan 2023 Planned End Date changed from 24 Jan 2024 to 27 Jan 2024.
25 Jan 2023 Planned End Date changed from 31 Jan 2023 to 24 Jan 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com